Abstract
T cells redirected to specific antigen targets with engineered chimeric antigen receptors(CARs)are emerging as powerful therapies in hematologic malignancies. Various CAR designs, manufacturing processes, and study populations, among other variables, have been studied and reported in clinical trials. The accumulating data supporting CAR-T cells therapy for disease such as chronic lymphocytic leukemia(CLL)and acute lymphocytic leukemia(ALL)highlight what may well become the next sea change in the care of patients with all types of hematologic neoplasia. The scientific symposium on CAR-T cells therapy inspires the mounting enthusiasm regarding this new treatment strategy. Here, the results of the reported clinical trials and the outlook for CAR-T cells therapies were reviewed and discussed. Many questions remain in the field of CAR-T cells directed to hematologic malignancies, but the encouraging response rates pave a wide road for future investigation. Key words: Chimeric antigen receptor T-cell; Hematologic malignancy; Adoptive immunotherapy; American Society of Hematology annual meeting
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
